

## AMENDMENTS

### In the Specification:

On page 91, please replace the paragraph which begins on line 29 with the following:

a<sup>1</sup> Replacement of residues Arg 118-Lys119-Tyr120-Thr121-Ser122 of FGF-2 (SEQ ID NO: 15) with the human sequence Ala-Gln-Phe-Pro-Asn (SEQ ID NO: 16) from the corresponding loop of the structural analogue IL-1 $\beta$  (115-119) was essentially performed as follows:

### In the Claims:

Please amend the claims as follows:

a<sup>2</sup> 46. (Amended) A method according to claim 1, wherein the step of introducing a vector into at least one coronary artery is performed coincident with or following infusion of the artery with a vasoactive agent.

a<sup>3</sup> 55. (Amended) A method according to claim 1, wherein said patient is a human.

a<sup>4</sup> 62. (Amended) The method of claim 58, wherein the conduit delivering blood to the tissue is selected from the group consisting of a coronary artery and a femoral artery.

a<sup>5</sup> 110. (Amended) A method according to claim 57, wherein the step of introducing a vector into at least one coronary artery is performed coincident with or following infusion of the artery with a vasoactive agent.

a<sup>6</sup> 119. (Amended) A method according to claim 57, wherein said patient is a human.

a<sup>7</sup> 152. (Amended) A kit comprising a gene therapy composition according to claim 121.